This phase I trial investigates the side effects and best dose of ²¹¹At-OKT10-B10 when given together with fludarabine, alone or in combination with cyclophosp…

Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma

~Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT04579523

Observational

Intervention to Enhance Cognitive Augmentation and Neuroplasticity (I-CAN)

This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \[I-CAN\]),…

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Multiple MyelomaRefractory B-Cell Non-Hodgkin Lymphoma+1 more

~Estimated

~$10 – $6,250

Ohio State University Comprehensive Cancer CenterNCT07609030

Phase 1

A Phase 1b Clinical Trial of CRISPR Delivered Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Multiple Myeloma

This phase Ib trial tests the safety, side effects and best dose of clustered regularly interspaced short palindromic repeats (CRISPR) delivered anti-B-cell ma…

Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma

~Estimated

~$10 – $7,500

Thomas Martin, MDNCT07340853

Observational

Prehabilitation in Patients With Multiple Myeloma Receiving CAR-T Therapy

This clinical trial evaluates whether prehabilitation with aerobic and resistance exercise improves physical fitness and quality of life outcomes in older pati…

Recurrent Multiple MyelomaRefractory Multiple Myeloma

~Estimated

~$10 – $6,250

Mayo ClinicNCT07045727

← PreviousPage 2 of 2Next →